12 Health Care Stocks Moving In Wednesday's After-Market Session
Portfolio Pulse from Benzinga Insights
After Wednesday's after-market session, several healthcare stocks experienced significant movements. Bone Biologics (BBLG) saw a 56.0% increase after Q3 earnings, while Exagen (XGN) and PAVmed (PAVM) also rose following their earnings reports. Conversely, Augmedix (AUGX), Impel Pharmaceuticals (IMPL), and others saw their stock prices decline. The movements were accompanied by notable trading volumes for some of the stocks.
November 15, 2023 | 9:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bone Biologics's stock soared by 56.0% to $0.81, with trading volume at 878.8% of its 100-day average after Q3 earnings release.
The significant rise in stock price and trading volume for Bone Biologics suggests a positive investor reaction to the Q3 earnings report, indicating a potential short-term upward trend.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
PAVmed shares rose by 11.31% to $0.25, with the market cap at $27.4 million after their recent Q3 earnings report.
The increase in PAVmed's stock price after the Q3 earnings report indicates a positive investor reaction, potentially leading to short-term growth.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Exagen's stock increased by 15.78% to $1.76 following their Q3 earnings announcement made two days ago.
Exagen's stock rise post-Q3 earnings suggests a favorable market response, which could lead to continued short-term appreciation.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Augmedix shares fell by 20.8% to $4.3, with trading volume at 29.6% of its 100-day average, and a market value of $175.4 million.
The decline in Augmedix's stock price, despite lower trading volume, could indicate negative sentiment, potentially leading to further short-term downside.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80
NEGATIVE IMPACT
Impel Pharmaceuticals' stock declined by 15.94% to $0.24, with a market value of $5.5 million.
Impel Pharmaceuticals' significant stock price drop could reflect investor concerns, suggesting a negative short-term outlook.
CONFIDENCE 75
IMPORTANCE 65
RELEVANCE 70